@article{MTMT:34813894,
	title = {In-Hospital Pulmonary Arterial Embolism after Catheter Ablation of over 45,000 Cardiac Arrhythmias: Individualized Case Analysis of Multicentric Data},
	url = {https://m2.mtmt.hu/api/publication/34813894},
	author = {Doldi, F. and Geβler, N. and Anwar, O. and Kahle, A.-K. and Scherschel, K. and Rath, B. and Köbe, J. and Lange, P.S. and Frommeyer, G. and Metzner, A. and Meyer, C. and Willems, S. and Kuck, K.-H. and Eckardt, L.},
	doi = {10.1055/s-0044-1785519},
	journal-iso = {THROMB HAEMOSTASIS},
	journal = {THROMBOSIS AND HAEMOSTASIS},
	unique-id = {34813894},
	issn = {0340-6245},
	year = {2024},
	eissn = {2567-689X}
}

@article{MTMT:34767109,
	title = {Racial differences in bleeding risk: An ecological epidemiological study comparing Korea and United Kingdom subjects},
	url = {https://m2.mtmt.hu/api/publication/34767109},
	author = {Kang, D.-S. and Yang, P.-S. and Kim, D. and Jang, E. and Yu, H.T. and Kim, T.-H. and Sung, J.H. and Pak, H.-N. and Lee, M.-H. and Lip, G.Y.H. and Joung, B.},
	doi = {10.1055/a-2269-1123},
	journal-iso = {THROMB HAEMOSTASIS},
	journal = {THROMBOSIS AND HAEMOSTASIS},
	unique-id = {34767109},
	issn = {0340-6245},
	abstract = {Background: This study aimed to evaluate racial differences in bleeding incidence by conducting an ecological epidemiological study using data from Korea and the UK. Methods: We included healthy participants from the Korean National Health Insurance Service-Health Screening and the UK Biobank who underwent health examinations between 2006 and 2010 and had no comorbidities or history of medication use. Finally, 112,750 East Asians (50.7% men, mean age 52.6 years) and 210,995 Caucasians (44.7% men, mean age 55.0 years) were analyzed. The primary outcome was composed of intracranial hemorrhage (ICH) and bleeding from the gastrointestinal, respiratory, and genitourinary systems. Results: During the follow-up, primary outcome events occurred in 2110 East Asians and in 6515 Caucasians. East Asians had a 38% lower five-year incidence rate compared to Caucasians (3.88 vs. 6.29 per 1000 person-years; incidence rate ratio [IRR] 0.62, 95% confidence interval [CI] 0.59.0.65). East Asians showed a lower incidence of major bleeding (IRR 0.86, 95% CI 0.81.0.91), bleeding from the gastrointestinal (IRR 0.53, 95% CI 0.49. 0.56), and genitourinary systems (IRR 0.49, 95% CI 0.44.0.53) compared to Caucasians. The incidence rates of ICH (IRR 3.20, 95% CI 2.67.3.84) and bleeding from the respiratory system (IRR 1.28, 95% CI 1.11.1.47) were higher in East Asians. Notably, East Asians consuming alcohol .3 times/week showed a higher incidence of the primary outcome than Caucasians (IRR 1.12, 95% CI 1.01.1.25). Conclusions: This ecological study revealed significant racial differences in bleeding incidence, influenced by anatomical sites and lifestyle habits, underscoring the need for tailored approaches in bleeding management based on race. © 2024 Georg Thieme Verlag. All rights reserved.},
	keywords = {Gastrointestinal bleeding; INTRACRANIAL HEMORRHAGE; Racial difference},
	year = {2024},
	eissn = {2567-689X}
}

@article{MTMT:34619159,
	title = {Early Time Courses of Recurrent Venous Thromboembolism and Bleeding during Apixaban or Dalteparin Therapy for Patients with Cancer},
	url = {https://m2.mtmt.hu/api/publication/34619159},
	author = {Cohen, Alexander T. and Creeper, Katherine J. and Alikhan, Raza and Er, Chaozer and Connors, Jean M. and Huisman, Menno V. and Munoz, Andres and Vescovo, Giorgio and Bauersachs, Rupert and Ageno, Walter and Agnelli, Giancarlo and Becattini, Cecilia},
	doi = {10.1055/s-0043-1778642},
	journal-iso = {THROMB HAEMOSTASIS},
	journal = {THROMBOSIS AND HAEMOSTASIS},
	unique-id = {34619159},
	issn = {0340-6245},
	abstract = {Background In patients with acute venous thromboembolism (VTE), the rates of recurrence and major bleeding are highest during the first weeks of anticoagulation. The CARAVAGGIO trial demonstrated noninferiority of apixaban to dalteparin for treatment of cancer-associated VTE without an increased risk of major bleeding. We compared the early time course of VTE recurrence and major bleeding events of apixaban compared with dalteparin at 7, 30, and 90 days of treatment in patients with cancer-associated VTE.Methods The study design of the CARAVAGGIO trial has been described. Eligible patients were randomly assigned to receive monotherapy with either apixaban or dalteparin for 6 months. The primary efficacy outcome was the incidence of objectively confirmed recurrent VTE. The primary safety outcome was major bleeding.Results In 1,155 patients, recurrent VTE after 7, 30, and 90 days occurred in 6 (1%), 15 (2.6%), and 27 (4.7%) patients in the apixaban arm versus 5 (0.9%), 20 (3.5%), and 36 (6.2%) patients respectively in the dalteparin arm. By day 7, 30, and 90, major bleeding events had occurred in 3 (0.5%), 9 (1.6%), and 16 (2.8%) patients in the apixaban group versus 5 (0.9%), 11 (1.9%), and 17 (2.9%) patients in the dalteparin group.Conclusion The frequencies of recurrent VTE and major bleeding events at 7, 30, and 90 days of apixaban compared with dalteparin were similar in patients with cancer-associated VTE. This supports the use of apixaban for the initiation and early phase of anticoagulant therapy in cancer-associated VTE.},
	keywords = {THROMBOSIS; CANCER; bleeding; Anticoagulants; dalteparin},
	year = {2024},
	eissn = {2567-689X}
}

@article{MTMT:34499168,
	title = {Identification of Factor XIII β-Sandwich Residues Mediating Glutamine Substrate Binding and Activation Peptide Cleavage.},
	url = {https://m2.mtmt.hu/api/publication/34499168},
	author = {Mohammed, Rameesa D Syed and Piell, Kellianne M and Maurer, Muriel C},
	doi = {10.1055/a-2220-7544},
	journal-iso = {THROMB HAEMOSTASIS},
	journal = {THROMBOSIS AND HAEMOSTASIS},
	unique-id = {34499168},
	issn = {0340-6245},
	abstract = {Factor XIII (FXIII) forms covalent crosslinks across plasma and cellular substrates and has roles in hemostasis, wound healing, and bone metabolism. FXIII activity is implicated in venous thromboembolism (VTE) and is a target for developing pharmaceuticals, which requires understanding FXIII - substrate interactions. Previous studies proposed the β-sandwich domain of the FXIII A subunit (FXIII-A) exhibits substrate recognition sites. Recombinant FXIII-A proteins (WT, K156E, F157L, R158Q/E, R171Q, and R174E) were generated to identify FXIII-A residues mediating substrate recognition. Proteolytic (FXIII-A*) and non-proteolytic (FXIII-A°) forms were analyzed for activation and crosslinking activities toward physiological substrates using SDS-PAGE and MALDI-TOF MS. All FXIII-A* variants displayed reduced crosslinking abilities compared to WT for Fbg αC (233 - 425), fibrin, and actin. FXIII-A* WT activity was greater than A°, suggesting the binding site is more exposed in FXIII-A*. With Fbg αC (233 - 425), FXIII-A* variants R158Q/E, R171Q, and R174E exhibited decreased activities approaching those of FXIII-A°. However, with a peptide substrate, FXIII-A* WT and variants showed similar crosslinking suggesting the recognition site is distant from the catalytic site. Surprisingly, FXIII-A R158E and R171Q displayed slower thrombin activation than WT, potentially due to loss of crucial H-bonding with neighboring activation peptide (AP) residues. In conclusion, FXIII-A residues K156, F157, R158, R171, and R174 are part of a binding site for physiological substrates [fibrin (α and γ) and actin]. Moreover, R158 and R171 control AP cleavage during thrombin activation. These investigations provide new molecular details on FXIII - substrate interactions that control crosslinking abilities.},
	year = {2024},
	eissn = {2567-689X}
}

@article{MTMT:34767105,
	title = {Thrombosis and Haemostasis 2023 Editors' Choice Papers},
	url = {https://m2.mtmt.hu/api/publication/34767105},
	author = {Weber, C. and Rigby, A. and Lip, G.Y.H.},
	doi = {10.1055/s-0043-1778032},
	journal-iso = {THROMB HAEMOSTASIS},
	journal = {THROMBOSIS AND HAEMOSTASIS},
	volume = {124},
	unique-id = {34767105},
	issn = {0340-6245},
	keywords = {Body Weight; HEMOSTASIS; THROMBOSIS; ARTICLE; human; editorial; risk factor; OBESITY; sex difference; drug comparison; blood clot lysis; Anticoagulation; thromboelastography; antiplatelet activity},
	year = {2024},
	eissn = {2567-689X},
	pages = {80-87}
}

@article{MTMT:34182341,
	title = {Non-vitamin K Antagonist Oral Anticoagulant, Warfarin, and ABC Pathway Adherence on Hierarchical Outcomes: Win Ratio Analysis of the COOL-AF Registry},
	url = {https://m2.mtmt.hu/api/publication/34182341},
	author = {Treewaree, S. and Lip, G.Y.H. and Krittayaphong, R.},
	doi = {10.1055/s-0043-1772773},
	journal-iso = {THROMB HAEMOSTASIS},
	journal = {THROMBOSIS AND HAEMOSTASIS},
	volume = {124},
	unique-id = {34182341},
	issn = {0340-6245},
	abstract = {Background Atrial fibrillation (AF) Better Care (ABC) pathway adherence is associated with improved outcomes. Clinical trials have shown that non-vitamin K antagonist oral anticoagulants (NOACs) are as least as effective as warfarin for stroke prevention in AF patients. The Win Ratio method, analyzing hierarchical composite outcomes considering event timing and severity, has limited data on its use in Asians. Objectives We aim to apply Win Ratio in a registry to access the comparative effectiveness of NOACs versus warfarin and ABC adherence versus nonadherence in Asian patients with AF. Methods Our study included nonvalvular AF patients from the nationwide prospective COOL-AF registry in Thailand. The NOAC-treated group was compared with the warfarin-treated group using the Win Ratio, with the following order: all-cause death, intracranial hemorrhage (ICH), ischemic stroke/transient ischemic attack/systemic embolism, non-ICH major bleeding, and myocardial infarction or heart failure. ABC pathway adherence versus nonadherence was also compared. AWin Ratio greater than 1.00 indicating a better outcome. Results The analysis included 2,568 patients, with 228 in the NOAC group and 2,340 in the warfarin group. The NOAC group hadmore wins than the warfarin group, with an unmatched Win Ratio of 1.64 (95% confidence interval [CI]: 1.22-2.20; p<0.001). When compared with nonadherence, ABC pathway adherence was associated with a Win Ratio of 1.57 (95% CI: 1.33-1.85; p<0.001). Conclusion This Win Ratio analysis demonstrates the significant benefits of NOACs over warfarin and ABC pathway adherence over nonadherence in reducing the composite outcome in patients with AF. © 2023 Georg Thieme Verlag. All rights reserved.},
	keywords = {THROMBOSIS; Anticoagulants; Atrial Fibrillation; ABC pathway; Hierarchical composite outcome},
	year = {2024},
	eissn = {2567-689X},
	pages = {69-79}
}

@article{MTMT:34220125,
	title = {Strategies for Tailored Antiplatelet Therapy After PCI: Unraveling Complexities, Embracing Nuances},
	url = {https://m2.mtmt.hu/api/publication/34220125},
	author = {Landolina, D. and Ammirabile, N. and Capodanno, D.},
	doi = {10.1055/a-2177-4220},
	journal-iso = {THROMB HAEMOSTASIS},
	journal = {THROMBOSIS AND HAEMOSTASIS},
	volume = {124},
	unique-id = {34220125},
	issn = {0340-6245},
	year = {2024},
	eissn = {2567-689X},
	pages = {497-499}
}

@article{MTMT:34173626,
	title = {Plasma Soluble Glycoprotein VI: A Biomarker of Bleeding},
	url = {https://m2.mtmt.hu/api/publication/34173626},
	author = {Schneider, D.J.},
	doi = {10.1055/a-2160-0368},
	journal-iso = {THROMB HAEMOSTASIS},
	journal = {THROMBOSIS AND HAEMOSTASIS},
	volume = {124},
	unique-id = {34173626},
	issn = {0340-6245},
	year = {2024},
	eissn = {2567-689X},
	pages = {307-309}
}

@article{MTMT:34173625,
	title = {Predicting Bleeding in Cancer-Associated Venous Thromboembolism: Another Milestone Achieved},
	url = {https://m2.mtmt.hu/api/publication/34173625},
	author = {Roldán, V. and Soler-Espejo, E. and Marin, F.},
	doi = {10.1055/s-0043-1775582},
	journal-iso = {THROMB HAEMOSTASIS},
	journal = {THROMBOSIS AND HAEMOSTASIS},
	volume = {124},
	unique-id = {34173625},
	issn = {0340-6245},
	year = {2024},
	eissn = {2567-689X},
	pages = {337-339}
}

@article{MTMT:34447368,
	title = {Dual antiplatelet (DAPT) or Dual Pathway Inhibition (DPI)},
	url = {https://m2.mtmt.hu/api/publication/34447368},
	author = {Goto, S. and Goto, S.},
	doi = {10.1055/a-2191-7627},
	journal-iso = {THROMB HAEMOSTASIS},
	journal = {THROMBOSIS AND HAEMOSTASIS},
	volume = {124},
	unique-id = {34447368},
	issn = {0340-6245},
	year = {2024},
	eissn = {2567-689X},
	pages = {274-276}
}